Los Angeles Capital Management LLC Sells 4,480 Shares of Progyny, Inc. (NASDAQ:PGNY)

Los Angeles Capital Management LLC trimmed its position in Progyny, Inc. (NASDAQ:PGNY – Get Rating) by 30.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 10,025 shares of the company’s stock after selling 4,480 shares during the quarter. Los Angeles Capital Management LLC’s holdings in Progyny were worth $505,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. Atticus Wealth Management LLC bought a new stake in shares of Progyny during the 3rd quarter worth $47,000. Fifth Third Bancorp lifted its holdings in shares of Progyny by 1,532.4% in the fourth quarter. Fifth Third Bancorp now owns 1,208 shares of the company’s stock worth $61,000 after acquiring an additional 1,134 shares during the last quarter. Captrust Financial Advisors boosted its stake in shares of Progyny by 19.1% in the 3rd quarter. Captrust Financial Advisors now owns 1,566 shares of the company’s stock valued at $88,000 after purchasing an additional 251 shares in the last quarter. Harbor Investment Advisory LLC grew its holdings in shares of Progyny by 89.3% during the 4th quarter. Harbor Investment Advisory LLC now owns 1,603 shares of the company’s stock valued at $81,000 after purchasing an additional 756 shares during the last quarter. Finally, Lindbrook Capital LLC acquired a new position in Progyny during the 4th quarter worth approximately $101,000. Institutional investors own 92.93% of the company’s stock.

PGNY has been the topic of several recent research reports. Zacks Investment Research raised Progyny from a “sell” rating to a “hold” rating in a report on Wednesday, March 2nd. TheStreet lowered shares of Progyny from a “c-” rating to a “d+” rating in a report on Friday, January 28th. Three analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $70.43.

In other news, Chairman David J. Schlanger sold 1,000 shares of the firm’s stock in a transaction dated Friday, February 11th. The stock was sold at an average price of $42.00, for a total value of $42,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Norman Payson sold 8,330 shares of the business’s stock in a transaction dated Wednesday, January 26th. The shares were sold at an average price of $38.46, for a total value of $320,371.80. The disclosure for this sale can be found here. Over the last quarter, insiders sold 560,356 shares of company stock valued at $23,806,895. 19.40% of the stock is currently owned by corporate insiders.

Shares of PGNY opened at $40.47 on Friday. The business has a 50-day moving average of $44.30 and a 200-day moving average of $48.70. The company has a market capitalization of $3.71 billion, a price-to-earnings ratio of 61.32, a price-to-earnings-growth ratio of 13.98 and a beta of 1.89. Progyny, Inc. has a 1 year low of $32.86 and a 1 year high of $68.32.

Progyny (NASDAQ:PGNY – Get Rating) last released its earnings results on Monday, February 28th. The company reported $0.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.04 by $0.11. The business had revenue of $127.55 million for the quarter, compared to analyst estimates of $134.87 million. Progyny had a net margin of 13.14% and a return on equity of 30.41%. Progyny’s revenue for the quarter was up 27.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.07 earnings per share. On average, research analysts predict that Progyny, Inc. will post 0.14 EPS for the current fiscal year.

Progyny Company Profile (Get Rating)

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.

See Also